Il trattamento medico
|
|
- Jessie Walton
- 6 years ago
- Views:
Transcription
1
2 III Sessione: La malattia in fase avanzata Il trattamento medico Emilio Bria Oncologia, Dipartimento di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona Padova, 21 Marzo 2016
3 Disclosures Advisory Boards/Honoraria/Speakers fee/consultant for: Astra-Zeneca, Celgene, Pfizer, Helsinn, MSD, Eli-Lilly, BMS, Novartis, Roche Research Support / Grants from: A.I.R.C. (Associazione Italiana Ricerca sul Cancro) I.A.S.L.C. (International Association for the Study of Lung Cancer) Fondazione Cariverona
4
5 Outcome of MBC: Real World Scenario 472 patients from 2004 to 2012 Bonotto M et al, The Oncologist 2014
6 Overall Strategy: AIOM Recommendation [1] [2] 1] Bone (Y/N) 2] Immunophenotype
7 Overall Strategy: ESO-ESMO Recommendation Expert opinion Treatment choice should take into account at least these factors: HR and HER-2 status, previous therapies and toxicities, DFI, tumour burden (defined as number and site of metastases), biological age, performance status, co-morbidities (including organ dysfunctions), menopausal status (for ET), need for a rapid disease/symptom control, socio-economic and psychological factors, available therapies in the patient's country and patient preference. A small but very important subset of patients with MBC, for example those with oligometastatic disease, can achieve complete remission and a long survival. A multimodal approach should be considered for these selected patients. A prospective clinical trial addressing this specific situation is needed. Cardoso F et al, The Breast 2014
8 Overall Strategy: AIOM Recommendation [1] [2] 1] Bone (Y/N) 2] Immunophenotype
9 Overall Strategy: AIOM Recommendation [3] [4] [5] 3] Disease Charachteristics 4] Menopausal Status 5] Horm. Exposure
10 Overall Strategy: ESO-ESMO Recommendation ER+/HER-2 negative ABC Endocrine therapy (ET) is the preferred option for hormone receptor positive disease, even in the presence of visceral disease, unless: Concern or proof of endocrine resistance Disease needing a fast response Optimal post-aromatase inhibitor treatment is uncertain. Available options include, but are not limited to: Tamoxifen Another AI (with a different mechanism of action) Fulvestrant HD Megestrol acetate Everolimus + AI For pre-menopausal women, ovarian suppression/ablation combined with additional endocrine therapy is the first choice. IA IA IA Cardoso F et al, The Breast 2014
11 Endocrine Maintenance: ESO-ESMO Definition Resistance Setting Relapse (months) Hormonal treatment Primary Adjuvant < 24 During Advanced < 6 During Secondary Adjuvant 24 < 12 after adjuvant Advanced 6 During During After adjuvant Cardoso F et al, The Breast 2014
12 Treatment Alghorith according to AIOM
13 Evolution of Treatment for Luminal MBC Palbociclib + Fulvestrant Modified by Frassoldati A, 2015
14 Molecular Portrait of MBC: Which pathways are guilty? Cirello et al, BCRT 2013 Ignatiadis M et al, NRCO 2013
15 BOLERO-2: OS Mature Results Open Issues: No OS benefit in absence of cross-over Extremely refractory patients Toxicity Piccart M, AO 2014
16 PALOMA-3: Final Analysis for PFS Open Issues: Immature for OS Toxicity [ex.: G3-4 Neutropenia 60% vs. <1%] Cristofanilli M et al, Lancet Oncol 2016
17 Targeted Agents: Adding BEVA to Horm. Therapy LEA [380 pts] CALGB [352 pts] LET [80%] or FUL [10%] LET [100%] Both: No difference in OS Martin M, JCO 2015 Dickler M, ASCO 2015
18 Poly-endocrine Therapy: Fulvestrant + Anastrozole FUL + ANA vs. ANA FUL + ANA vs. ANA Pts: 707; PFS Pts: 514; TTP Different Pts Features Metha NEJM 2012 Bergh JCO 2012
19 Overall Strategy: Which role for Chemotherapy? Courtesy of Frassoldati A, 2015
20 Chemotherapy for MBC: ESO-ESMO Recommendation Expert opinion Visceral Crisis: Severe organ dysfunction as assessed by signs and symptoms, laboratory studies, and rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases, but implies: Important visceral compromise leading to a clinical indication for a more rapidly efficacious therapy, particularly since another treatment option at progression will probably not be possible. Cardoso F et al, The Breast 2014
21 Chemotherapy for MBC: ESO-ESMO Recommendation Sequential monotherapy is the preferred choice for MBC. Combination CT should be reserved for patients with: rapid clinical progression, lifethreatening visceral metastases need for rapid symptom and/or disease control. In patients pre-treated (in the adjuvant or metastatic setting) with an anthracycline and a taxane, and who do not need combination chemotherapy, single agent capecitabine, vinorelbine or eribulin are the preferred choices. Additional choices include gemcitabine, platinum agents, taxanes, and liposomal anthracyclines. The decision should be individualized and take into account different toxicity profiles, previous exposure, patient preferences, and country availability. IA IB Cardoso F et al, The Breast 2014
22 Overall Strategy: Comorbidities in the Real World Modified - Montemurro F, AIOM 2014
23 Overall Strategy: How choose (best) treatment?
24 Chemotherapy for MBC: ASCO Recommendation Recommendations Endocrine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor positive metastatic breast cancer unless improvement is medically necessary (eg, immediately life-threatening disease). Single agent is preferable to combination chemotherapy, and longer planned duration improves outcome but must be balanced against toxicity. There is no single optimal first-line or subsequent line chemotherapy, and choice of treatment will be determined by multiple factors including prior therapy, toxicity, performance status, comorbid conditions, and patient preference. The role of bevacizumab remains controversial.. not currently an approved indication for bevacizumab in the United States because the weight of evidence shows no significant survival benefit. Parthridge A et al JCO 2014
25 Chemotherapy for MBC: The role of Bevacizumab PFS OS Current International Recommendations:..Bevacizumab can only therefore be considered as an option in selected cases.. the role of bevacizumab is controversial, and this therapy should be considered (where available) with single-agent chemotherapy only when there is immediately life-threatening disease or severe symptoms, in view of improved response rates. Miles et al, Ann Oncol 2013 ESMO Cardoso et al, Ann Oncol 2014 ASCO Partridge et al, JCO 2014
26 Chemotherapy Maintenance: Modern Evidences N=94 N=287/360 planned N=185/360 planned N=91 Gligorov et al, Lancet Oncol 2014
27 Chemotherapy for MBC: Predictors of activity/efficacy TNBC: Differential Effect of CARBO according to BRCA Tutt SABCS 2014
28 Hormonal Maintenance: ESO-ESMO Recommendation
29 Hormonal Maintainace: Modern Evidences Tredan et al, Ann Oncol 2016
30 Hormonal Maintenance: Modern Evidences Multicenter study: patients non progressive after First Line Chemotherapy p= OT maint (66 pts) No OT maint (66 pts) 33.9% 20.3% p= OT maint (78 pts) No OT maint (54 pts) 62.3% 43.2% PFS OS Curves adjusted for Propensity Score Carbognin L et al, AIOM 2015
31 Predictors of Efficacy: Are all Luminal BCs equal? Cirello et al, BCRT 2013
32 Predictors of Efficacy: Are all Luminal BCs equal? Ades et al, JCO 2014
33 Predictors of Efficacy: Are all Luminal BCs equal? Turner ESMO 2014
34 Overall Strategy: AIOM Recommendation [1] [2] 1] Bone (Y/N) 2] Immunophenotype
35 HER2 Positive MBC: Clinical Scenario Expected benefit in OS: > 24 months (additional 3-4 months) Expected benefit in PFS: > 7.5 months (additional months) Michiels S et al, Ann Oncol 2016
36 Overview of improvements with Pertuzumab & T-DM1 CLEOPATRA OS PFS Increased ORR More FN EMILIA TH3RESA OS PFS OS PFS Increased ORR and CBR; Less G3 and 4 toxicity Increased ORR Less G3 and 4 toxicity Swain et al, NEJM 2015; Verma et al, NEJM 2012; Krop et al, Lancet Oncol 2014
37 Current treatment options for HER2-positive MBC Qualifying statement: Although clinicians may discuss using endocrine therapy with or without HER2-targeted therapy, the majority of patients will still receive chemotherapy plus HER2- targeted therapy. ASCO Panelists, 2014
38 Issues for Pertuzumab: Does previous Trastuzumab affect efficacy? Subgroup N Doce + T Doce + T + P HR Progression-Free Survival Prior adjuvant trastuzumab Prior adjuvant chemo (no trast) No prior chemo Swain S et al, NEJM 2015 Despite the inferior median PFS, T-based therapy was an effective first-line treatment for patients relapsing after previous T. TFI, type of 1st site of disease relapse, and HR status should be considered in the choice of the best 1st-line treatment option for HER2-positive MBC. Lambertini M et al, Oncologist 2015
39 Issues for Pertuzumab & TDM1: Does disease pattern affect outcome (PFS)? CLEOPATRA Baseline EMILIAcharacteristic Disease involvement Visceral Nonvisceral Total n HR (95% CI) 0.55 (0.45, 0.67) 0.96 (0.71, 1.30) T DM1 better Cap + Lap better TH3RESA Swain et al, NEJM 2015; Verma et al, NEJM 2012; Krop et al, Lancet Oncol 2014
40 Issues for TDM1: Does long-term exposure to anti HER2 therapy cause loss of HER2 addiction? T-DM1 vs. TPC + Trast. T-DM1 vs. TPC TPS (198 pts) T-DM1 (404 pts) Prior Exposure to anti-her2 therapy Trastuzumab 198 (100%) 404 (100%) Duration (months) Lapatinib 198 (100%) 404 (100%) Duration (months) Krop et al, Lancet Oncol 2014
41 Could we further optimize First line anti HER2 treatment? Ellis P et al, ASCO 2015
42 MARIANNE: Primary End-Point (PFS) Ellis P et al, ASCO 2015
43 MARIANNE: Secondary End-Points Ellis P et al, ASCO 2015
44 CLEOPATRA & MARIANNE: New Clinical Scenario (OS) CLEOPATRA MARIANNE Expected benefit in OS: > 50 months (additional months) Expected benefit in PFS: > 18 months (additional 6-7 months) Swain S et al, NEJM 2015 Ellis P et al, ASCO 2015
45 Evolution of Treatment of HER2 Positive MBC 2009 Lapatinib + trastuzumab 2001 Pivotal Trial Trastusuzmab Beyond Progression 2012 Emilia 2015 Marianne 1996 First Trial 2006 Lapatinib Capecitabine Anti HER2 therapy + endocrine therapy 2011 Cleopatra 2013 Th3resa Try to identify markers of resistance, sensitivity and to elaborate strategies to improve the efficacy of HER2 targeting in the clinic by newer molecules/approaches
46 EMILIA: PFS according to PIK3CA Baselga Jet al, CCR 2016
47 HER2 Positive MBC: The PI3K/Akt/mTOR axis Role of PI3K/Akt/PTEN alterations on Everolimus-related benefit (combined analysis of the Bolero 1 and 3 studies) Slamon D et al, ASCO 2014
48 Medical Treatment for MBC: Conclusions - 1 Luminal BC: the optimization of HT and targeted agents significantly lower the adoption of chemotherapy, preserving QoL without affecting survival. TNBC: chemotherapy according to genetic features may represent a future perspective. HER2 Positive: dramatic improvement in prognosis with the new drugs.
49 Medical Treatment for MBC: Conclusions - 2 Common Issue for Clinical Practice: Which one the best sequence? How to deal with costs? EMA dumps the responsibility to AIFA, AIFA dumps the responsibility to Local Governments. Common Principle: To identify markers of resistance, sensitivity to improve the efficacy of (any) treatment
50
A vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationImmunoterapia e farmaci innovativi
Immunoterapia e farmaci innovativi Emilio Bria Oncologia Medica, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Padova, 29 Ottobre 2015 Disclosures Advisory
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationCriteri di selezione dei pazienti Criteri restrittivi vs.
Criteri di selezione dei pazienti Criteri restrittivi vs. inclusivi Conseguenze su trasferibilità e precisione delle evidenze Emilio Bria Oncologia Medica, Dipart. di Medicina, Università di Verona, Az.
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationSessione 4: La malattia metastatica. La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G.
Sessione 4: La malattia metastatica La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo giusyricciardi81@hotmail.it
More informationAdvances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationHighlights. Padova,
Highlights P Pronzato Padova, 17.11.2012 Last 12 Months Main Meetings SABCS 2011 (San Antonio) EBCC 8 2012 (Wien) ASCO 2012 (Chicago) ESMO/ECCO 2012 (Wien) The Medical Oncology Job Risk Manager Strategy
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationLA MALATTIA METASTATICA. La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O.
LA MALATTIA METASTATICA La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O. Narni-Amelia (TR) Outline Re-testing metastatic disease Chemo- vs endocrine-therapy
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationSystemic therapy for HER2+ Advanced Breast Cancer
Systemic therapy for HER2+ Advanced Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationBreast Cancer Advanced Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Advanced Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch How to Guidelines and Consensus Breast Cancer Advanced Disease Prognosis Clonal (and diagnostic) evolution: Biopsy
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationDEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc
DEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc Revue des essais cliniques en cours et perspectives Dr Cristian Villanueva CHRU Besançon
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationChallenges and Success: Treatment of Metastatic Breast Cancer 2012
Challenges and Success: Treatment of Metastatic Breast Cancer 2012 Hope S. Rugo University of California San Francisco Helen Diller Family Comprehensive Cancer Center This presentation is the intellectual
More informationI SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI. Marta Bonotto Department of Oncology, University Hospital of Udine, Italy
I SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI Marta Bonotto Department of Oncology, University Hospital of Udine, Italy Breast Cancer Metastatic Breast Cancer (MBC) Metastatic Breast Cancer (MBC)
More informationSYSTEMIC THERAPY FOR HER-2+ ABC
SYSTEMIC THERAPY FOR HER-2+ ABC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC
More informationCurrent Management of Breast Cancer
Current Management of Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program Coordinator
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informatione-session 381 BCY3 - Highlights of the 3rd ESO-ESMO Breast Cancer in Young Women International Conference
Expert: Dr Olivia Pagani, Oncology Institute of Southern Switzerland, Lugano, Switzerland Discussant: Dr Fedro Alessandro Peccatori, European Institute of Oncology, Milan, Italy e-session 381 BCY3 - Highlights
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationOptimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer
Optimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer Dr Antonio Llombart-Cussac, MD, PhD Medical Oncology Division Hospital Arnau Vilanova, Valencia, Spain Disclaimer The contents herein
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationDEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationEndocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationUpdate HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More informationAGO e. V. in der DGGG e.v. sowie in der DKG e.v.
AGO e. V. in der DGGG e.v. sowie in der DKG e.v. Guidelines Breast Version 2015.1 www.ago-online.de Disease-Free and Overall Survival in Metastatic Breast Cancer AGO e. V. in der DGGG e.v. sowie in der
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationRecenti avanzamenti nel carcinoma della mammella
Recenti avanzamenti nel carcinoma della mammella PierFranco Conte Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche Università di Padova Pierfranco Conte IOV Istituto Oncologico Veneto
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationNewly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center
Newly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center A Diagnosis of Advanced Breast Cancer Leads To Many Immediate Questions How am I supposed
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationPI3K/AKT/mTOR Inhibitors in Breast Cancer
PI3K/AKT/mTOR Inhibitors in Breast Cancer Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Global Breast Cancer Conference 2015 Outline Overview of PI3K/Akt/mTOR Pathway Rationale
More information